Alder BioPharmaceuticals, Inc. announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD1910 as a preventive treatment for migraine. ALD1910 is an investigational monoclonal antibody (mAb) that inhibits pituitary adenylate cyclase-activating polypeptide (PACAP), an important signaling molecule in the pathophysiology of migraine. ALD1910 represents a potential new therapeutic option, focusing on a new pathway in migraine prevention that is distinct from the inhibition of calcitonin gene-related peptide (CGRP), a neuropeptide believed to play a key role in mediating and initiating migraine attacks. PACAP and its receptors have been found across the pain-processing pathway, and increased levels of PACAP have been found in blood samples of patients experiencing a migraine attack.i In preclinical studies, ALD1910 has been shown to be a selective, high-affinity antibody that demonstrated in vivo engagement of the PACAP target. The Phase 1 double-blind, placebo-controlled study of ALD1910 will enroll approximately 100 healthy men and women between the ages of 18 and 55 and will assess the safety, tolerability and pharmacokinetic profile of ALD1910 at various doses.